Apixaban and Middle insomnia - a phase IV clinical study of FDA data

Summary:

Middle insomnia is found among people who take Apixaban, especially for people who are female, 60+ old.

The phase IV clinical study analyzes which people take Apixaban and have Middle insomnia. It is created by eHealthMe based on reports of 49,223 people who have side effects when taking Apixaban from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Nov, 30, 2022

49,223 people reported to have side effects when taking Apixaban.
Among them, 7 people (0.01%) have Middle insomnia.

What is Apixaban?

Apixaban has active ingredients of apixaban. eHealthMe is studying from 49,394 Apixaban users for its effectiveness, alternative drugs and more.

What is Middle insomnia?

Middle insomnia (difficulty returning to sleep after awakening either in the middle of the night) is found to be associated with 1,496 drugs and 941 conditions by eHealthMe.

Number of Apixaban and Middle insomnia reports submitted per year:

Gender of people who have Middle insomnia when taking Apixaban *:

female: 66.67 %
male: 33.33 %

Age of people who have Middle insomnia when taking Apixaban *:

Common drugs people take besides Apixaban *:

Common side effects people have besides Middle insomnia *:

Fatigue (feeling of tiredness): 6 people, 85.71%
Heart Rate Increased: 5 people, 71.43%
Nasopharyngitis (inflammation of the nasopharynx): 5 people, 71.43%
Dizziness: 5 people, 71.43%
Productive Cough: 5 people, 71.43%
High Blood Pressure: 5 people, 71.43%
Peripheral Swelling: 4 people, 57.14%
Breathing Difficulty: 4 people, 57.14%
Asthma: 4 people, 57.14%
Nausea (feeling of having an urge to vomit): 4 people, 57.14%

Common conditions people have *:

Asthma: 4 people, 57.14%
Muscle Spasms (muscle contraction): 1 person, 14.29%
Intervertebral Disc Disorder (spinal disc disorder): 1 person, 14.29%
Idiopathic Pulmonary Fibrosis (chronic lung disease): 1 person, 14.29%
High Blood Cholesterol: 1 person, 14.29%
Burkitt Lymphoma (cancer of the lymphatic system): 1 person, 14.29%
Back Pain: 1 person, 14.29%
Agitation (state of anxiety or nervous excitement): 1 person, 14.29%

* Approximation only. Some reports may have incomplete information.

Do you take Apixaban and have Middle insomnia?

Check whether Middle insomnia is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Middle insomnia and when was it recovered:

Middle insomnia in Apixaban

Expand to all the drugs that have ingredients of apixaban:

Middle insomnia and drugs with ingredients of apixaban

Alternative drugs to, pros and cons of Apixaban:

Apixaban (49,394 reports)

Common Apixaban side effects:

Browse all side effects of Apixaban:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Middle insomnia treatments and more:

Middle insomnia (18,494 reports)

COVID vaccines that are related to Middle insomnia:

Common drugs associated with Middle insomnia:

All the drugs that are associated with Middle insomnia:

Middle insomnia (1,496 drugs)

Common conditions associated with Middle insomnia:

Asthma: 2,427 reports
Insomnia: 1,554 reports
Parkinson's disease: 765 reports
Depression: 724 reports
High blood cholesterol: 629 reports

All the conditions that are associated with Middle insomnia:

Middle insomnia (941 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on apixaban (the active ingredients of Apixaban) and Apixaban (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.